<DOC>
	<DOCNO>NCT01896154</DOCNO>
	<brief_summary>The aim study estimate effect size 5-week consumption period different dietary non-digestible polysaccharide ( NPS ) antibody response influenza vaccination cellular immunity healthy volunteer ( age ≥ 50 ) clarify whether NPS may enable enhancement immune defence estimate sample size confirmative trial . Furthermore effect faecal microbiota metabolite investigate .</brief_summary>
	<brief_title>Pilot Study Effect Size Non-digestible Polysaccharides ( NPS ) Immunity</brief_title>
	<detailed_description>The study conduct frame collaborative project 'FibeBiotics ' ( Nr . 289517 ) ( Fibers support Gut Immune function Elderly - From polysaccharide compound health claim ) within Seventh Framework Programme ( FP7 ) Research Technological Development European Union ( EU ) .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Freeliving postmenopausal woman men age ≥ 50 year willing influenza vaccination season 2012/2013 willingness abstain far possible food supplement contain probiotic , prebiotic supplement , ferment product , supplement contain vitamin mineral well willing sustain low dietary fibre diet 7 week . write informed consent Subjects enrol another clinical study last 4 week Subjects already vaccinate influenza 20122013 either influenza vaccine use present study another influenza vaccine vaccination influenza within previous 10 month suffer influenza influenzalike illness within previous 10 month vaccination within 2 month study symptom common infectious disease ( CID ) airways organ system e.g . gastrointestinal tract last 4 week inclusion know congenital , acquire iatrogenic immunodeficiency ( e.g . HIV , chemotherapy , immunosuppression ) active autoimmune disease allergy hypersensitivity component vaccine ( e. g. chicken egg protein , certain antibiotic ) ( s. . 9.2 ) allergy hypersensitivity component test product ( e. g. yeast , gluten , shiitake mushroom ) allergy latex know coeliac disease ( gluten enteropathy ) bowel movement le 3 time per week subject , meet 2 Rome III criterion constipation take laxative regular basis severe chronic disease ( cancer , IBD , malabsorption , malnutrition , chronic inflammatory disease , renal , hepatic cardiac disease , COPD , respiratory insufficiency ) chronic abdominal pain malformation finger systemic treatment topical treatment likely interfere evaluation study parameter : antibiotic , intestinal respiratory antiseptic , antirheumatics , antiphlogistics ( except aspirin equivalent product prevent aggregation platelet blood clot ) steroid prescribe chronic inflammatory diseases treatment likely interfere study outcome ( e.g . laxative , body weight management and/or medication ) treatments calcium antagonist nitrate alpha blocker diabetes mellitus drug therapy severe neurological , cognitive psychiatric disease surgery intervention require general anaesthesia within 2 month study vegetarian , vegan eat disorder ( e.g . anorexia , bulimia ) alcohol drug abuse pregnancy lactation legal incapacity blood parameter : Hb &lt; 12 g/dL Liver transaminases ( ALT , AST ) &gt; 2fold increase Serum creatinine &gt; 1,2 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>dietary fiber , influenza vaccination , HI titre</keyword>
</DOC>